BACKGROUND: Because of its safety, "single-shot" pulsed field ablation (PFA) catheters have been developed for pulmonary vein isolation (PVI). However, most atrial fibrillation (AF) ablation procedures are performed with focal catheters to permit flexibility of lesion sets beyond PVI. OBJECTIVES: This study sought to determine the safety and efficacy of a focal ablation catheter able to toggle between radiofrequency ablation (RFA) or PFA to treat paroxysmal or persistent AF. METHODS: In a first-in-human study, a focal 9-mm lattice tip catheter was used for PFA posteriorly and either irrigated RFA (RF/PF) or PFA (PF/PF) anteriorly. Protocol-driven remapping was at ∼3 months postablation. The remapping data prompted PFA waveform evolution: PULSE1 (n = 76), PULSE2 (n = 47), and the optimized PULSE3 (n = 55). RESULTS: The study included 178 patients (paroxysmal/persistent AF = 70/108). Linear lesions, either PFA or RFA, included 78 mitral, 121 cavotricuspid isthmus, and 130 left atrial roof lines. All lesion sets (100%) were acutely successful. Invasive remapping of 122 patients revealed improvement of PVI durability with waveform evolution: PULSE1: 51%; PULSE2: 87%; and PULSE3: 97%. After 348 ± 652 days of follow-up, the 1-year Kaplan-Meier estimates for freedom from atrial arrhythmias were 78.3% ± 5.0% and 77.9% ± 4.1% for paroxysmal and persistent AF, respectively, and 84.8% ± 4.9% for the subset of persistent AF patients receiving the PULSE3 waveform. There was 1 primary adverse event-inflammatory pericardial effusion not requiring intervention. CONCLUSIONS: AF ablation with a focal RF/PF catheter allows efficient procedures, chronic lesion durability, and good freedom from atrial arrhythmias-for both paroxysmal and persistent AF. (Safety and Performance Assessment of the Sphere-9 Catheter and the Affera Mapping and RF/PF Ablation System to Treat Atrial Fibrillation; NCT04141007 and NCT04194307).

Cardiac Electrophysiology Section Department of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA

Centre for Cardiology and Angiology Department of Cardiovascular Diseases Vilnius University Vilnius Lithuania

Department of Cardiology Homolka Hospital Prague Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Helmsley Electrophysiology Center Department of Cardiology Icahn School of Medicine at Mount Sinai New York New York USA

Texas Cardiac Arrhythmia Institute at St David's Medical Center Austin Texas USA

University of Bordeaux CHU Bordeaux IHU LIRYC ANR 10 IAHU 04 Bordeaux France

000      

00000naa a2200000 a 4500

001      

bmc23016739

003      

CZ-PrNML

005      

20231026105603.0

007      

ta

008      

231013s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jacep.2023.04.002 $2 doi

035    __

$a (PubMed)37227340

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Reddy, Vivek Y $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic; Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: vivek.reddy@mountsinai.org

245    12

$a A Focal Ablation Catheter Toggling Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation / $c VY. Reddy, P. Peichl, E. Anter, G. Rackauskas, J. Petru, M. Funasako, K. Minami, JS. Koruth, A. Natale, P. Jais, G. Marinskis, A. Aidietis, J. Kautzner, P. Neuzil

520    9_

$a BACKGROUND: Because of its safety, "single-shot" pulsed field ablation (PFA) catheters have been developed for pulmonary vein isolation (PVI). However, most atrial fibrillation (AF) ablation procedures are performed with focal catheters to permit flexibility of lesion sets beyond PVI. OBJECTIVES: This study sought to determine the safety and efficacy of a focal ablation catheter able to toggle between radiofrequency ablation (RFA) or PFA to treat paroxysmal or persistent AF. METHODS: In a first-in-human study, a focal 9-mm lattice tip catheter was used for PFA posteriorly and either irrigated RFA (RF/PF) or PFA (PF/PF) anteriorly. Protocol-driven remapping was at ∼3 months postablation. The remapping data prompted PFA waveform evolution: PULSE1 (n = 76), PULSE2 (n = 47), and the optimized PULSE3 (n = 55). RESULTS: The study included 178 patients (paroxysmal/persistent AF = 70/108). Linear lesions, either PFA or RFA, included 78 mitral, 121 cavotricuspid isthmus, and 130 left atrial roof lines. All lesion sets (100%) were acutely successful. Invasive remapping of 122 patients revealed improvement of PVI durability with waveform evolution: PULSE1: 51%; PULSE2: 87%; and PULSE3: 97%. After 348 ± 652 days of follow-up, the 1-year Kaplan-Meier estimates for freedom from atrial arrhythmias were 78.3% ± 5.0% and 77.9% ± 4.1% for paroxysmal and persistent AF, respectively, and 84.8% ± 4.9% for the subset of persistent AF patients receiving the PULSE3 waveform. There was 1 primary adverse event-inflammatory pericardial effusion not requiring intervention. CONCLUSIONS: AF ablation with a focal RF/PF catheter allows efficient procedures, chronic lesion durability, and good freedom from atrial arrhythmias-for both paroxysmal and persistent AF. (Safety and Performance Assessment of the Sphere-9 Catheter and the Affera Mapping and RF/PF Ablation System to Treat Atrial Fibrillation; NCT04141007 and NCT04194307).

650    _2

$a lidé $7 D006801

650    12

$a fibrilace síní $x chirurgie $7 D001281

650    _2

$a katétry $7 D057785

650    12

$a katetrizační ablace $x škodlivé účinky $x metody $7 D017115

650    12

$a venae pulmonales $x chirurgie $7 D011667

650    12

$a ablace $7 D055011

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Peichl, Petr $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Anter, Elad $u Cardiac Electrophysiology Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA

700    1_

$a Rackauskas, Gediminas $u Centre for Cardiology and Angiology, Department of Cardiovascular Diseases, Vilnius University, Vilnius, Lithuania

700    1_

$a Petru, Jan $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic

700    1_

$a Funasako, Moritoshi $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic

700    1_

$a Minami, Kentaro $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic

700    1_

$a Koruth, Jacob S $u Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

700    1_

$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas, USA

700    1_

$a Jais, Pierre $u University of Bordeaux, CHU Bordeaux, IHU LIRYC (L'Institut des maladies du rhythm cardiaque) ANR-10-IAHU-04, Bordeaux, France

700    1_

$a Marinskis, Germanas $u Centre for Cardiology and Angiology, Department of Cardiovascular Diseases, Vilnius University, Vilnius, Lithuania

700    1_

$a Aidietis, Audrius $u Centre for Cardiology and Angiology, Department of Cardiovascular Diseases, Vilnius University, Vilnius, Lithuania

700    1_

$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Neuzil, Petr $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic

773    0_

$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 9, č. 8 Pt 3 (2023), s. 1786-1801

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37227340 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20231013 $b ABA008

991    __

$a 20231026105558 $b ABA008

999    __

$a ok $b bmc $g 2000327 $s 1203101

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 9 $c 8 Pt 3 $d 1786-1801 $e 20230416 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518

LZP    __

$a Pubmed-20231013